JP2021504420A - 微生物叢調節のためのヒトミルクオリゴ糖およびその合成組成物 - Google Patents

微生物叢調節のためのヒトミルクオリゴ糖およびその合成組成物 Download PDF

Info

Publication number
JP2021504420A
JP2021504420A JP2020529534A JP2020529534A JP2021504420A JP 2021504420 A JP2021504420 A JP 2021504420A JP 2020529534 A JP2020529534 A JP 2020529534A JP 2020529534 A JP2020529534 A JP 2020529534A JP 2021504420 A JP2021504420 A JP 2021504420A
Authority
JP
Japan
Prior art keywords
hmo
human
gastrointestinal
abundance
human milk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020529534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504420A5 (https=
Inventor
ルイーセ・クリスティーネ・ヴィクスネス
ブルース・マコンネル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycom AS
Original Assignee
Glycom AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycom AS filed Critical Glycom AS
Publication of JP2021504420A publication Critical patent/JP2021504420A/ja
Publication of JP2021504420A5 publication Critical patent/JP2021504420A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2020529534A 2017-11-30 2018-11-30 微生物叢調節のためのヒトミルクオリゴ糖およびその合成組成物 Pending JP2021504420A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201700680 2017-11-30
DKPA201700680 2017-11-30
DKPA201700690 2017-12-05
DKPA201700690 2017-12-05
PCT/IB2018/059501 WO2019106620A1 (en) 2017-11-30 2018-11-30 Human milk oligosaccharides and synthetic compositions thereof for microbiota modulation

Publications (2)

Publication Number Publication Date
JP2021504420A true JP2021504420A (ja) 2021-02-15
JP2021504420A5 JP2021504420A5 (https=) 2022-01-06

Family

ID=66664406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020529534A Pending JP2021504420A (ja) 2017-11-30 2018-11-30 微生物叢調節のためのヒトミルクオリゴ糖およびその合成組成物

Country Status (7)

Country Link
US (1) US20200323921A1 (https=)
EP (1) EP3716983A4 (https=)
JP (1) JP2021504420A (https=)
KR (1) KR102741265B1 (https=)
CN (1) CN111683665A (https=)
BR (1) BR112020010843A2 (https=)
WO (1) WO2019106620A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023096870A (ja) * 2021-12-27 2023-07-07 株式会社明治 アッカーマンシア属細菌の増殖促進剤
WO2023176950A1 (ja) 2022-03-18 2023-09-21 株式会社明治 腸管内での細菌の増殖制御用組成物及びその利用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11234992B2 (en) * 2018-02-28 2022-02-01 The Regents Of The University Of California Methods and therapies for treating atherosclerosis and/or hyperlipidemia using oligosaccharides
CN113194960A (zh) 2018-12-19 2021-07-30 格礼卡姆股份公司 用于治疗使用低fodmap饮食的人的组合物和方法
EP3897663A4 (en) * 2018-12-21 2022-09-07 Glycom A/S COMPOSITION AND METHOD FOR PROMOTING HEALING OF THE INTESTINAL BARRIER
KR20220017988A (ko) * 2019-06-05 2022-02-14 글리콤 에이/에스 비-셀리악 밀 및/또는 글루텐 민감성을 앓고 있는 환자에서 증상 치료에 사용하기 위한 모유 올리고사카라이드
JP2022548785A (ja) * 2019-09-24 2022-11-21 プロラクタ バイオサイエンス，インコーポレイテッド 炎症性疾患及び免疫疾患の治療のための組成物及び方法
JP2023501111A (ja) * 2019-11-14 2023-01-18 グリコム・アクティーゼルスカブ 腸管における胆汁酸プロファイルを均衡させるための合成組成物
CA3178744C (en) 2020-05-13 2023-11-14 Ardythe L. Morrow Fucosylated oligosaccharides for prevention of coronavirus infection
WO2021231750A1 (en) * 2020-05-13 2021-11-18 Glycosyn LLC 2'-fucosyllactose for the prevention and treatment of coronavirus-induced inflammation
US11896603B2 (en) * 2020-06-12 2024-02-13 The Regents Of The University Of California Oligosaccharide as therapeutic agent for alcohol associated liver disease
EP4188391A1 (en) * 2020-07-31 2023-06-07 Abbott Laboratories Method of preventing, reducing or delaying fatty liver disease
CN116490079A (zh) * 2020-12-04 2023-07-25 雀巢产品有限公司 用于在个体中使用以支持夜间睡眠持续时间的包含人乳低聚糖的组合物
KR102456307B1 (ko) * 2021-11-10 2022-10-19 충남대학교산학협력단 3’-시알릴락토오스, 6’-시알릴락토오스 또는 이의 염을 유효성분으로 포함하는 감염에 의한 다발성 장기부전의 예방 또는 치료용 조성물
CN115089596A (zh) * 2022-06-20 2022-09-23 自然资源部第三海洋研究所 新琼寡糖用于制备治疗抑郁症产品的新用途
WO2024126578A1 (en) * 2022-12-13 2024-06-20 Dsm Ip Assets B.V. Synthetic composition comprising a human milk oligosaccharide for microbiota modulation
CN119138609B (zh) * 2024-11-19 2025-02-25 飞鹤(吉林)乳品有限公司 母乳低聚糖改善母婴肠道菌群的用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525487A (ja) * 2003-12-05 2007-09-06 チルドレンズ ホスピタル メディカル センター オリゴ糖組成物および感染症の治療における該組成物の使用
JP2012532195A (ja) * 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
WO2013025104A1 (en) * 2011-08-16 2013-02-21 Friesland Brands B.V. Nutritional compositions comprising human milk oligosaccharides and uses thereof
JP2015512936A (ja) * 2012-04-13 2015-04-30 トラスティーズ オブ ボストン カレッジ プレバイオティクス組成物およびその使用方法
WO2016139333A1 (en) * 2015-03-05 2016-09-09 Nestec S.A. Compositions for use in the prevention or treatment of gastrointestinal infections/inflammations in infants or young children
US20160287637A1 (en) * 2014-12-08 2016-10-06 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
US20160367577A1 (en) * 2014-12-08 2016-12-22 Glycom A/S Synthetic composition for treating metabolic disorders
WO2017046711A1 (en) * 2015-09-14 2017-03-23 Glycom A/S Synthetic composition for microbiota modulation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2944690B1 (en) * 2010-10-11 2017-12-20 Jennewein Biotechnologie GmbH Novel fucosyltransferases and their applications
US20120171166A1 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
PT2672844E (pt) * 2011-02-10 2015-02-04 Nestec Sa Modulação do crescimento de bifidobactérias utilizando uma combinação de oligossacáridos identificados no leite humano
US20140187474A1 (en) * 2011-02-16 2014-07-03 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
WO2012158517A1 (en) * 2011-05-13 2012-11-22 Glycosyn LLC The use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
HK1199607A1 (en) * 2011-08-29 2015-07-10 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
WO2013161820A1 (ja) * 2012-04-23 2013-10-31 国立大学法人京都大学 ビフィズス菌の増殖促進用組成物
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
GB201312713D0 (en) * 2013-03-22 2013-08-28 Weaver Connie M Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption
US20160120915A1 (en) * 2013-06-10 2016-05-05 New York University Methods for manipulating immune responses by altering microbiota
PL3209673T5 (pl) * 2014-10-24 2023-10-23 Glycom A/S Mieszaniny hmo
EP3212198B1 (en) * 2014-10-29 2020-12-23 Glycom A/S Synthetic composition and method for promoting mucosal healing
CN108367031A (zh) * 2015-10-05 2018-08-03 瑞士达沃斯高山气候和医学研究院 嗜黏蛋白阿克曼氏菌用于治疗炎症病况的用途
US10780103B2 (en) * 2015-10-28 2020-09-22 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
RU2744199C2 (ru) * 2016-01-26 2021-03-03 Сосьете Де Продюи Нестле С.А. Композиция, содержащая олигосахариды грудного молока, применяемая для младенцев или детей младшего возраста в целях профилактики или лечения аллергических реакций
WO2018157900A1 (en) * 2017-03-01 2018-09-07 Glycom A/S Synthetic composition for microbiota modulation
EP3634429A4 (en) * 2017-05-09 2020-11-04 Glycom A/S SYNTHETIC COMPOSITION FOR MICROBIOTE MODULATION
US20180333426A1 (en) * 2017-05-17 2018-11-22 Mead Johnson Nutrition Company Nutritional composition with human milk oligosaccharides and uses thereof
WO2018215961A1 (en) * 2017-05-24 2018-11-29 Glycom A/S Synthetic composition comprising oligosaccharides and its use in medical treatment.
WO2019123316A1 (en) * 2017-12-22 2019-06-27 Glycom A/S Composition comprising hmos for preventing or reducing nociception

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525487A (ja) * 2003-12-05 2007-09-06 チルドレンズ ホスピタル メディカル センター オリゴ糖組成物および感染症の治療における該組成物の使用
JP2012532195A (ja) * 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
WO2013025104A1 (en) * 2011-08-16 2013-02-21 Friesland Brands B.V. Nutritional compositions comprising human milk oligosaccharides and uses thereof
JP2015512936A (ja) * 2012-04-13 2015-04-30 トラスティーズ オブ ボストン カレッジ プレバイオティクス組成物およびその使用方法
US20160287637A1 (en) * 2014-12-08 2016-10-06 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
US20160367577A1 (en) * 2014-12-08 2016-12-22 Glycom A/S Synthetic composition for treating metabolic disorders
WO2016139333A1 (en) * 2015-03-05 2016-09-09 Nestec S.A. Compositions for use in the prevention or treatment of gastrointestinal infections/inflammations in infants or young children
WO2017046711A1 (en) * 2015-09-14 2017-03-23 Glycom A/S Synthetic composition for microbiota modulation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CANI PD: "Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila", FRONT MICROBIOL, vol. Vol.22, No.8, Article No. 1765, JPN6022046391, 22 September 2017 (2017-09-22), pages 1 - 8, ISSN: 0005113475 *
CASTILLO-COURTADE L: "Attenuation of food allergy symptoms following treatment with human milk oligosaccharides in a mouse", ALLERGY, vol. 70, no. 9, JPN6022046387, 2015, pages 1091 - 1102, ISSN: 0005113473 *
HIPPE B: "Abundance and diversity of GI microbiota rather than IgG4 levels correlate with abdominal inconvenie", ENDOCR METAB IMMUNE DISORD DRUG TARGETS, vol. 14, no. 1, JPN6022046393, 2014, pages 67 - 75, ISSN: 0005113477 *
NOORA A. OTTMAN: "Host immunostimulation and substrate utilization of the gut symbiont Akkeramnasia muciniphila", PHD THESIS, WAGENINGEN UNIVERSITY, JPN6022046390, 2015, pages 1 - 23, ISSN: 0005113474 *
TARR AJ: "The prebiotics 3'Sialyllactose and 6'Sialyllactose diminish stressor-induced anxiety-like behavior a", BRAIN BEHAV IMMUN, vol. 50, JPN6022046385, 2015, pages 166 - 177, ISSN: 0005113472 *
WANG L: "Low relative abundances of the mucolytic bacterium Akkermansia muciniphila and Bifidobacterium spp.", APPL ENVIRON MICROBIOL, vol. Vo.77, No.18, JPN6022046394, 2011, pages 6718 - 6721, ISSN: 0005113476 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023096870A (ja) * 2021-12-27 2023-07-07 株式会社明治 アッカーマンシア属細菌の増殖促進剤
WO2023176950A1 (ja) 2022-03-18 2023-09-21 株式会社明治 腸管内での細菌の増殖制御用組成物及びその利用

Also Published As

Publication number Publication date
WO2019106620A1 (en) 2019-06-06
US20200323921A1 (en) 2020-10-15
EP3716983A1 (en) 2020-10-07
KR102741265B1 (ko) 2024-12-11
EP3716983A4 (en) 2022-03-02
KR20200091438A (ko) 2020-07-30
BR112020010843A2 (pt) 2020-11-10
CN111683665A (zh) 2020-09-18

Similar Documents

Publication Publication Date Title
US11696921B2 (en) Synthetic composition for microbiota modulation
US12063949B2 (en) Mixture of HMOs
KR102741265B1 (ko) 미생물총 조절을 위한 인간 밀크 올리고당 및 그의 합성 조성물
US11291677B2 (en) Synthetic composition for microbiota modulation
JP2021152062A (ja) 過敏性腸症候群の治療のための合成組成物および方法
US11278558B2 (en) Synthetic composition for microbiota modulation
US11541067B2 (en) HMO compositions and methods for reducing detrimental proteolytic metabolites
CN107106584A (zh) 用于治疗代谢障碍的合成组合物
JP2023503541A (ja) Ｈｍｏの混合物
CN111526879A (zh) 用于减少或预防疲劳和/或改善注意力或专注力的一种或多种hmo
JP2021504421A (ja) 小麦過敏症を処置するためのｈｍｏの混合物
US11554131B2 (en) Mixture of HMOs for treating autoimmune diseases
US20160367577A1 (en) Synthetic composition for treating metabolic disorders
JP2022513524A (ja) 低ｆｏｄｍａｐ食を使用してヒトを治療するための組成物および方法
RU2857185C2 (ru) Композиции для стимулирования ускоренной выработки бутирата у детей младшего возраста

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211122

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220307

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220310

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230424

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230725